Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Rodrigo Velázquez-Moctezuma"'
Autor:
Jannick Prentoe, Christoph M. Janitzek, Rodrigo Velázquez-Moctezuma, Andreas Soerensen, Thomas Jørgensen, Stine Clemmensen, Vladislav Soroka, Susan Thrane, Thor Theander, Morten A. Nielsen, Ali Salanti, Jens Bukh, Adam F. Sander
Publikováno v:
npj Vaccines, Vol 7, Iss 1, Pp 1-10 (2022)
Abstract Development of B-cell-based hepatitis C virus (HCV) vaccines that induce broadly neutralizing antibodies (bNAbs) is hindered by extensive sequence diversity and low immunogenicity of envelope glycoprotein vaccine candidates, most notably sol
Externí odkaz:
https://doaj.org/article/17c5271bc53545d784e5135a4f4c87f6
Autor:
Long V. Pham, Rodrigo Velázquez-Moctezuma, Ulrik Fahnøe, Laura Collignon, Priyanka Bajpai, Christina Sølund, Nina Weis, Kenn Holmbeck, Jannick Prentoe, Jens Bukh
Publikováno v:
Viruses, Vol 14, Iss 11, p 2527 (2022)
Hepatitis C virus (HCV) genotype 4 is highly prevalent in the Middle East and parts of Africa. Subtype 4d has recently spread among high-risk groups in Europe. However, 4d infectious culture systems are not available, hampering studies of drugs, as w
Externí odkaz:
https://doaj.org/article/a1d9cda048864f47943b04977b05abfb
Autor:
Jannick Prentoe, Christoph M Janitzek, Rodrigo Velázquez-Moctezuma, Louise Goksøyr, Rebecca W Olsen, Margherita Fanalista, Elias H Augestad, Susan Thrane, Anne F Pihl, Judith M Gottwein, Adam F Sander, Jens Bukh
Publikováno v:
PLoS ONE, Vol 16, Iss 7, p e0255336 (2021)
Yearly, about 1.5 million people become chronically infected with hepatitis C virus (HCV) and for the 71 million with chronic HCV infection about 400,000 die from related morbidities, including liver cirrhosis and cancer. Effective treatments exist,
Externí odkaz:
https://doaj.org/article/66c39541f9e1496cbb7f3e0e0d294e1a
Autor:
Zhen-Yong Keck, Brian G Pierce, Patrick Lau, Janine Lu, Yong Wang, Alexander Underwood, Rowena A Bull, Jannick Prentoe, Rodrigo Velázquez-Moctezuma, Melanie R Walker, Fabio Luciani, Johnathan D Guest, Catherine Fauvelle, Thomas F Baumert, Jens Bukh, Andrew R Lloyd, Steven K H Foung
Publikováno v:
PLoS Pathogens, Vol 15, Iss 5, p e1007772 (2019)
Cumulative evidence supports a role for neutralizing antibodies contributing to spontaneous viral clearance during acute hepatitis C virus (HCV) infection. Information on the timing and specificity of the B cell response associated with clearance is
Externí odkaz:
https://doaj.org/article/02ca33a0a5d144a7a284f9c9f72f99b4
Autor:
Rodrigo Velázquez-Moctezuma, Elias H. Augestad, Matteo Castelli, Christina Holmboe Olesen, Nicola Clementi, Massimo Clementi, Nicasio Mancini, Jannick Prentoe
Publikováno v:
Vaccines, Vol 9, Iss 3, p 291 (2021)
Hepatitis C virus (HCV) is a major causative agent of acute and chronic hepatitis. It is estimated that 400,000 people die every year from chronic HCV infection, mostly from severe liver-related diseases such as cirrhosis and liver cancer. Although H
Externí odkaz:
https://doaj.org/article/96598d1f2dc14d2885ea21be9b9dc792
Autor:
Garazi Peña Alzua, Anne Finne Pihl, Anna Falden Offersgaard, Rodrigo Velázquez-Moctezuma, Elias Honeroed Augestad, Ulrik Fahnøe, Christian Kjaerulff Mathiesen, Mansun Law, Jannick Prentoe, Jens Bukh, Judith Margarete Gottwein
Publikováno v:
Proceedings, Vol 50, Iss 1, p 5 (2020)
Epitope shielding is suggested as an important mechanism mediating the escape of hepatitis C virus (HCV) from host-neutralizing antibodies (nAb). [...]
Externí odkaz:
https://doaj.org/article/a61c0ec673c84eaa9be32c06e8214dec
Publikováno v:
PLoS Pathogens, Vol 13, Iss 2, p e1006214 (2017)
Hepatitis C virus (HCV) is a major cause of end-stage liver diseases. With 3-4 million new HCV infections yearly, a vaccine is urgently needed. A better understanding of virus escape from neutralizing antibodies and their corresponding epitopes are i
Externí odkaz:
https://doaj.org/article/bcb2d371b85440ce93dc3cc2ed113c7c
Autor:
Garazi P. Alzua, Anne F. Pihl, Anna Offersgaard, Rodrigo Velázquez‐Moctezuma, Carlos R. Duarte Hernandez, Elias H. Augestad, Ulrik Fahnøe, Christian K. Mathiesen, Henrik Krarup, Mansun Law, Jannick Prentoe, Jens Bukh, Judith M. Gottwein
Publikováno v:
Alzua, G P, Pihl, A F, Offersgaard, A, Velázquez-Moctezuma, R, Duarte Hernandez, C R, Augestad, E H, Fahnøe, U, Mathiesen, C K, Krarup, H, Law, M, Prentoe, J, Bukh, J & Gottwein, J M 2023, ' Identification of novel neutralizing determinants for protection against HCV ', Hepatology, vol. 73, no. 3, pp. 982-996 . https://doi.org/10.1002/hep.32772
Alzua, G P, Pihl, A F, Offersgaard, A, Velázquez-Moctezuma, R, Hernandez, C R D, Augestad, E H, Fahnøe, U, Mathiesen, C K, Krarup, H, Law, M, Prentoe, J, Bukh, J & Gottwein, J M 2023, ' Identification of novel neutralizing determinants for protection against HCV ', Hepatology, vol. 77, no. 3, pp. 982-996 . https://doi.org/10.1002/hep.32772
Alzua, G P, Pihl, A F, Offersgaard, A, Velázquez-Moctezuma, R, Hernandez, C R D, Augestad, E H, Fahnøe, U, Mathiesen, C K, Krarup, H, Law, M, Prentoe, J, Bukh, J & Gottwein, J M 2023, ' Identification of novel neutralizing determinants for protection against HCV ', Hepatology, vol. 77, no. 3, pp. 982-996 . https://doi.org/10.1002/hep.32772
BACKGROUND AND AIMS: HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine. N-linked glycosylation of viral envelope proteins is a key mechanism for such evasio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ee8ddda5099418631770b24f323c860
https://curis.ku.dk/portal/da/publications/identification-of-novel-neutralizing-determinants-for-protection-against-hcv(8ae9404e-763e-4513-aa0e-d6bc1800cc97).html
https://curis.ku.dk/portal/da/publications/identification-of-novel-neutralizing-determinants-for-protection-against-hcv(8ae9404e-763e-4513-aa0e-d6bc1800cc97).html
Autor:
Rodrigo Velázquez-Moctezuma, Jens Bukh, Andrea Galli, Jannick Prentoe, Richard J. Wang, Mansun Law, Harvey J. Alter, Elias H. Augestad
Publikováno v:
Proceedings of the National Academy of Sciences. 116:10039-10047
About two million new cases of hepatitis C virus (HCV) infections annually underscore the urgent need for a vaccine. However, this effort has proven challenging because HCV evades neutralizing antibodies (NAbs) through molecular features of viral env
Autor:
Ariadna Grinyo, Elias H. Augestad, Mayda Hernandez, Netanel Tzarum, Kenna Nagy, Robyn L. Stanfield, Linling He, Mansun Law, Robert E. Lanford, Rodrigo Velázquez-Moctezuma, Deborah Chavez, Xiaohe Lin, Jens Bukh, Erick Giang, Ian A. Wilson, Mallorie E. Fouch, Jannick Prentoe, Benjamin J. Doranz, Jiang Zhu, Fang Chen
Publikováno v:
Immunity
Chen, F, Tzarum, N, Lin, X, Giang, E, Velázquez-Moctezuma, R, Augestad, E H, Nagy, K, He, L, Hernandez, M, Fouch, M E, Grinyó, A, Chavez, D, Doranz, B J, Prentoe, J, Stanfield, R L, Lanford, R, Bukh, J, Wilson, I A, Zhu, J & Law, M 2021, ' Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins ', Immunity, vol. 54, no. 4, pp. 781-796.e4 . https://doi.org/10.1016/j.immuni.2021.02.013
Chen, F, Tzarum, N, Lin, X, Giang, E, Velázquez-Moctezuma, R, Augestad, E H, Nagy, K, He, L, Hernandez, M, Fouch, M E, Grinyó, A, Chavez, D, Doranz, B J, Prentoe, J, Stanfield, R L, Lanford, R, Bukh, J, Wilson, I A, Zhu, J & Law, M 2021, ' Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins ', Immunity, vol. 54, no. 4, pp. 781-796.e4 . https://doi.org/10.1016/j.immuni.2021.02.013
Human IGHV1-69-encoded broadly neutralizing antibodies (bnAbs) that target the hepatitis C virus (HCV) envelope glycoprotein (Env) E2 are important for protection against HCV infection. An IGHV1-69 ortholog gene, VH1.36, is preferentially used for bn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a9b240bcbc75d463054a656be6471f1
https://europepmc.org/articles/PMC8046733/
https://europepmc.org/articles/PMC8046733/